PharmaCyte Biotech Inc (PMCB)

[rcstock]

In my opinion, we successfully completed 1) and are working on OPTIMIZING
(2) and (3). (4) should be a continuous effort.
After enduring what has been a lengthy and time-consuming checklist of FDA-required tests, reports, documents and meetings, PharmaCyte's shareholders should take comfort in knowing that the list of items they're waiting on has now been trimmed to (1) the encapsulated live cells fully filling the Cell-in-a-Box capsules, (2) the fully-filled capsules being placed into syringes and frozen, (3) FDA-required testing of the capsules, and finally (4) the writing of the reports and submission of the IND application to the FDA.